{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:24:09Z","timestamp":1787664249009,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10147-026-03144-6","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:30:10Z","timestamp":1785839410000},"page":"1781-1790","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Olaparib maintenance versus placebo or standard of care in ovarian cancer: a biomarker-driven systematic review and meta-analysis of randomized trials"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8215-1449","authenticated-orcid":false,"given":"Farida","family":"Namozova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7154-8692","authenticated-orcid":false,"given":"Isadora","family":"Mamede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Alves","family":"Felippe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9103-9119","authenticated-orcid":false,"given":"Carlos","family":"Stecca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"issue":"14","key":"3144_CR1","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1001\/jama.2025.9495","volume":"334","author":"G Caruso","year":"2025","unstructured":"Caruso G, Weroha SJ, Cliby W (2025) Ovarian cancer: a review. JAMA 334(14):1278\u20131291. https:\/\/doi.org\/10.1001\/jama.2025.9495","journal-title":"JAMA"},{"key":"3144_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158125","author":"L Ch","year":"2022","unstructured":"Ch L, Km S, Kh C (2022) The molecular mechanisms of actions, effects, and clinical implications of PARP inhibitors in epithelial ovarian cancers: a systematic review. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23158125","journal-title":"Int J Mol Sci"},{"issue":"5","key":"3144_CR3","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1001\/jamaoncol.2023.7322","volume":"10","author":"S Morganti","year":"2024","unstructured":"Morganti S, Marra A, De Angelis C et al (2024) PARP inhibitors for breast cancer treatment: a review. JAMA Oncol 10(5):658\u2013670. https:\/\/doi.org\/10.1001\/jamaoncol.2023.7322","journal-title":"JAMA Oncol"},{"key":"3144_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1335196","volume":"14","author":"M Arcieri","year":"2024","unstructured":"Arcieri M, Tius V, Andreetta C et al (2024) How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature. Front Oncol 14:1335196. https:\/\/doi.org\/10.3389\/fonc.2024.1335196","journal-title":"Front Oncol"},{"issue":"12","key":"3144_CR5","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","volume":"22","author":"S Banerjee","year":"2021","unstructured":"Banerjee S, Moore KN, Colombo N et al (2021) Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 22(12):1721\u20131731. https:\/\/doi.org\/10.1016\/S1470-2045(21)00531-3","journal-title":"Lancet Oncol"},{"key":"3144_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1435029","volume":"14","author":"Q Zhao","year":"2024","unstructured":"Zhao Q, Bai L, Tan Y et al (2024) Limitations of homologous recombination status testing and poly (ADP-ribose) polymerase inhibitor treatment in the current management of ovarian cancer. Front Oncol 14:1435029. https:\/\/doi.org\/10.3389\/fonc.2024.1435029","journal-title":"Front Oncol"},{"issue":"11","key":"3144_CR7","doi-asserted-by":"publisher","first-page":"e2541648","DOI":"10.1001\/jamanetworkopen.2025.41648","volume":"8","author":"S Petousis","year":"2025","unstructured":"Petousis S, Kahramanoglu I, Appenzeller-Herzog C et al (2025) PARP inhibitor maintenance after first-line chemotherapy in advanced-stage epithelial ovarian cancer: a systematic review and meta-analysis. JAMA Netw Open 8(11):e2541648. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.41648","journal-title":"JAMA Netw Open"},{"issue":"1","key":"3144_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-025-01599-1","volume":"18","author":"S Ji","year":"2025","unstructured":"Ji S, Chen L, Yu Y et al (2025) A comprehensive comparison of PARP inhibitors as maintenance therapy in platinum-sensitive recurrent ovarian cancer: a systematic review and network meta-analysis. J Ovarian Res 18(1):18. https:\/\/doi.org\/10.1186\/s13048-025-01599-1","journal-title":"J Ovarian Res"},{"key":"3144_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"3144_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-25","volume":"14","author":"J IntHout","year":"2014","unstructured":"IntHout J, Ioannidis JPA, Borm GF (2014) The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol 14:25. https:\/\/doi.org\/10.1186\/1471-2288-14-25","journal-title":"BMC Med Res Methodol"},{"issue":"8","key":"3144_CR11","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","volume":"34","author":"I Ray-Coquard","year":"2023","unstructured":"Ray-Coquard I, Leary A, Pignata S et al (2023) Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial. Ann Oncol 34(8):681\u2013692. https:\/\/doi.org\/10.1016\/j.annonc.2023.05.005","journal-title":"Ann Oncol"},{"issue":"3","key":"3144_CR12","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.22.01549","volume":"41","author":"P DiSilvestro","year":"2023","unstructured":"DiSilvestro P, Banerjee S, Colombo N et al (2023) Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial. J Clin Oncol 41(3):609\u2013617. https:\/\/doi.org\/10.1200\/JCO.22.01549","journal-title":"J Clin Oncol"},{"key":"3144_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.11.020","author":"P Harter","year":"2025","unstructured":"Harter P, Trillsch F, Okamoto A et al (2025) Durvalumab with carboplatin\/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2025.11.020","journal-title":"Ann Oncol"},{"key":"3144_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.101704","author":"I Vergote","year":"2025","unstructured":"Vergote I, Cibula D, Powell M et al (2025) Chemotherapy with or without pembrolizumab followed by maintenance with olaparib or placebo for first-line treatment of advanced BRCA non-mutated epithelial ovarian cancer: results from the randomized phase 3 ENGOT-OV43\/GOG-3036\/KEYLYNK-001 study. Int J Gynecol Cancer. https:\/\/doi.org\/10.1016\/j.ijgc.2025.101704","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"3144_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","volume":"16","author":"AM Oza","year":"2015","unstructured":"Oza AM, Cibula D, Benzaquen AO et al (2015) Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 16(1):87\u201397. https:\/\/doi.org\/10.1016\/S1470-2045(14)71135-0","journal-title":"Lancet Oncol"},{"issue":"12","key":"3144_CR16","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.annonc.2023.09.3110","volume":"34","author":"E Pujade-Lauraine","year":"2023","unstructured":"Pujade-Lauraine E, Selle F, Scambia G et al (2023) Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO\/ENGOT-ov38): a phase IIIb trial. Ann Oncol 34(12):1152\u20131164. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.3110","journal-title":"Ann Oncol"},{"issue":"9","key":"3144_CR17","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/s41416-018-0271-y","volume":"119","author":"M Friedlander","year":"2018","unstructured":"Friedlander M, Matulonis U, Gourley C et al (2018) Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer 119(9):1075\u20131085. https:\/\/doi.org\/10.1038\/s41416-018-0271-y","journal-title":"Br J Cancer"},{"issue":"8","key":"3144_CR18","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","volume":"15","author":"J Ledermann","year":"2014","unstructured":"Ledermann J, Harter P, Gourley C et al (2014) Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15(8):852\u2013861. https:\/\/doi.org\/10.1016\/S1470-2045(14)70228-1","journal-title":"Lancet Oncol"},{"issue":"15","key":"3144_CR19","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"J Ledermann","year":"2012","unstructured":"Ledermann J, Harter P, Gourley C et al (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366(15):1382\u20131392. https:\/\/doi.org\/10.1056\/NEJMoa1105535","journal-title":"N Engl J Med"},{"issue":"9","key":"3144_CR20","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F et al (2017) Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 18(9):1274\u20131284. https:\/\/doi.org\/10.1016\/S1470-2045(17)30469-2","journal-title":"Lancet Oncol"},{"key":"3144_CR21","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ejca.2022.07.022","volume":"174","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2022","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Desauw C, Heitz F et al (2022) Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: main analysis of second progression-free survival in the phase III PAOLA-1\/ENGOT-ov25 trial. Eur J Cancer 174:221\u2013231. https:\/\/doi.org\/10.1016\/j.ejca.2022.07.022","journal-title":"Eur J Cancer"},{"issue":"25","key":"3144_CR22","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S et al (2019) Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 381(25):2416\u20132428. https:\/\/doi.org\/10.1056\/NEJMoa1911361","journal-title":"N Engl J Med"},{"issue":"5","key":"3144_CR23","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","volume":"22","author":"A Poveda","year":"2021","unstructured":"Poveda A, Floquet A, Ledermann JA et al (2021) Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 22(5):620\u2013631. https:\/\/doi.org\/10.1016\/S1470-2045(21)00073-5","journal-title":"Lancet Oncol"},{"key":"3144_CR24","unstructured":"National Comprehensive Cancer Network (2025) NCCN clinical practice guidelines in oncology: ovarian cancer\/fallopian tube cancer\/primary peritoneal cancer. Published online July 16, 2025. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1453"},{"key":"3144_CR25","doi-asserted-by":"publisher","unstructured":"Tew WP, Lacchetti C, Kohn EC, for the PARP Inhibitors in the Management of Ovarian Cancer Guideline Expert Panel (2022) Poly(ADP-Ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 40(33):3878\u20133881. https:\/\/doi.org\/10.1200\/JCO.22.01934","DOI":"10.1200\/JCO.22.01934"},{"issue":"11","key":"3144_CR26","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1002\/cncr.29082","volume":"121","author":"UA Matulonis","year":"2015","unstructured":"Matulonis UA, Oza AM, Ho TW et al (2015) Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials. Cancer 121(11):1737\u20131746. https:\/\/doi.org\/10.1002\/cncr.29082","journal-title":"Cancer"},{"issue":"1","key":"3144_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ygyno.2013.11.008","volume":"132","author":"TJ Herzog","year":"2014","unstructured":"Herzog TJ, Armstrong DK, Brady MF et al (2014) Ovarian cancer clinical trial endpoints: society of Gynecologic Oncology white paper. Gynecol Oncol 132(1):8\u201317. https:\/\/doi.org\/10.1016\/j.ygyno.2013.11.008","journal-title":"Gynecol Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03144-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03144-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03144-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:08:47Z","timestamp":1787663327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03144-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3144"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03144-6","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"14 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}